Royal Bank Of Canada Issues Pessimistic Forecast for Jasper Therapeutics (NASDAQ:JSPR) Stock Price

Jasper Therapeutics (NASDAQ:JSPR) had its price objective dropped by research analysts at Royal Bank Of Canada from $4.00 to $3.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s target price would suggest a potential upside of 257.57% from the company’s current price.

Several other equities analysts also recently commented on JSPR. UBS Group started coverage on Jasper Therapeutics in a research report on Monday, March 23rd. They issued a “neutral” rating on the stock. TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Tuesday, April 21st. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $13.14.

Jasper Therapeutics Trading Down 12.5%

JSPR stock traded down $0.12 during midday trading on Friday, reaching $0.84. 92,244 shares of the company’s stock traded hands, compared to its average volume of 547,916. Jasper Therapeutics has a 52-week low of $0.62 and a 52-week high of $7.19. The stock has a market cap of $23.49 million, a P/E ratio of -0.18 and a beta of 3.07. The stock’s 50-day moving average is $1.02 and its 200 day moving average is $1.44.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.47. As a group, research analysts expect that Jasper Therapeutics will post -2.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in JSPR. Acadian Asset Management LLC purchased a new stake in Jasper Therapeutics during the first quarter valued at approximately $46,000. Engineers Gate Manager LP purchased a new position in shares of Jasper Therapeutics in the second quarter worth $78,000. Panagora Asset Management Inc. acquired a new stake in shares of Jasper Therapeutics during the fourth quarter worth $35,000. Voleon Capital Management LP purchased a new stake in shares of Jasper Therapeutics during the third quarter valued at $50,000. Finally, XTX Topco Ltd acquired a new position in shares of Jasper Therapeutics in the 2nd quarter valued at $152,000. 79.85% of the stock is owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.